A CDC committee has voted to expand its respiratory syncytial virus vaccine recommendation to include all people aged 50 to 59 years.

A key group of government advisers voted to expand the use of vaccines for a common respiratory illness, providing a boost to manufacturers whose sales fell sharply last year.The Advisory Committee on Immunization Practices recommended that adults age 50 to 59 who are at high risk of severe respiratory syncytial virus get a single dose of the vaccine.

GSK GSK and Pfizer PFE announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended the expanded use of their respiratory syncytial virus (RSV) vaccines.